ArticleScientific reports2025
Prognostic factors for survival after allogeneic transplantation in acute myeloid leukemia in Iran using censored quantile regression model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-term outcomes and GVHD in allogeneic hematopoietic cell transplantation abroad: a 14-year UAE multi-center cohort.BJC reports · 2026Article
- Article
- Pandora's Box of AML: HowBiomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell transplantation (HSCT) emerged over sixty years ago as a groundbreaking and potentially curative treatment for patients with acute myeloid leukemia (AML) who were not responding to chemotherapy. In this study, we aimed to investigate prognostic factors for survival after allo-HSCT in AML patients. This retrospective cohort study was carried out using data from 742 adult AML patients underwent allo-HSCT. we analysis prognostic factors for survival after allo-HSCT with censored quantile regression model. The 5-year OS, DFS and GRFS rates were 58, 53, and 30%, respectively. OS for recipients older than 35 years was 0.95 and 1.12 years lower than that for recipients under 35 years in the 25th and 40th percentiles, respectively. Compared to patients in their CRІ, those with CRІІІ disease experienced a decrease in OS at the 25th and 40th percentiles by 1.72 and 3.72 years, respectively. Moreover, OS for ABO matched patients was 0.92 and 1.29 years longer than that of patients with an ABO major mismatch. This study could assist oncologists and hematologists in understanding the prognostic factors affecting patient survival across various survival ranges, thereby potentially extending patients' lifespans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.